Navigation Links
Martek Announces Fourth Quarter and FY 2008 Financial Results
Date:12/11/2008

- 900 Repurchase from sale-leaseback transaction - (3,910) Capitalization of intangible assets (3,895) (6,010) Net cash used in investing activities (22,130) (10,724) Financing activities: Repayments of notes payable and other long-term obligations, net (8,917) (1,013) Repayments under revolving credit facility, net - (36,000) Proceeds from stock option exercises and other, net 10,021 3,272 Net cash provided by (used in) financing activities 1,104 (33,741) Net change in cash, cash equivalents 85,522 1,395 Cash and cash equivalents, beginning of period 16,973 15,578 Cash and cash equivalents, end of period $102,495 $16,973 CONTACT Kyle Stults Investor Relations (410) 740-0081 kstults@martek.com
'/>"/>
SOURCE Martek Biosciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Martek to Announce Third Quarter 2007 Results on September 5, 2007
2. Martek to Present at Upcoming UBS Conference
3. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
4. Martek Announces Settlement of OmegaTech Milestone Litigation
5. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
6. European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed
7. Martek to Present at Upcoming ThinkEquity Partners Conference
8. Martek Announces Fourth Quarter and FY 2007 Financial Results
9. Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea
10. Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer
11. Challenge Spreadable Butter Now Features Marteks lifesDHA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce that it ... Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center is an ... and how agriculture impacts their daily lives. This unique exhibit also features a birthing ...
(Date:7/30/2015)... 2015 According to a new ... Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract ... Trial), by End Users - Global Forecast to 2020", ... reach USD 2,107.99 million by 2020 from USD 1,034.93 ... Browse more than 75 ...
(Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
(Date:7/29/2015)... 30, 2015 Sanofi, a ... the second quarter of 2015. CEO Olivier ... its performance in different businesses. Watch ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in the ... - Performance drivers - Diabetes ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, ... has been granted,U.S. Patent 7,264,798 entitled "Sensitization ... Virus." The claims describe a method of,using ... drug,resistance to chemotherapeutic agents. "Recent research ...
... Hyatt New York on Monday, September 10th, ... a biopharmaceutical company developing patient-specific, active,immunotherapies for the ... Ph.D., President and Chief Executive Officer, will present ... 1:30 p.m. Eastern,time on Monday, September 10, 2007. ...
... in ... Hong Kong, China, SAN ... leading China biometrics company Miaxis,Biometrics Co., Ltd has been officially selected ... The news has been,announced at a gala dinner during the ,Red ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent 2Miaxis Biometrics Named as 'Red Herring 100 Asia' Award Winner for 2007 2Miaxis Biometrics Named as 'Red Herring 100 Asia' Award Winner for 2007 3
(Date:7/31/2015)... The 10 th International Conference on Genomics (ICG-10, ... in Shenzhen , China ... anniversary this year. Since its inauguration in 2006, ICG ... in the ,omics, fields, and is one of the most ... focuses on recent breakthroughs and advances in ,omics, research that ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, ... for gene function analysis and biomarker discovery, announced ... (sgRNA) Knockout Library targeting all human protein coding ... permanently "knock out" a gene,s function. Cellecta,s new ... high throughput screening tool so that researchers can ...
(Date:7/27/2015)... JOSE, Calif. , July 27, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... ® touchscreen solution for its stylish smartwatch. ... for its proven reliability, low power and highly ... a wet finger. Huawei designers also required a ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... from “vile and cynical exploitation?by the alternative medicines industry, argues ... estimated that up to 80% of all patients with cancer ... help treat their cancer, writes Jonathan Waxman, Professor of Oncology ... the use of many of these approaches is obtuse ?one ...
... chemotherapy with short-term structural changes in cognitive areas ... Published in the January 1, 2007 issue of ... the American Cancer Society, the study reveals that ... regions of the brain associated with memory, analysis ...
... by other patients whose treatment has to be dropped to ... New guidance from the National Institute for health and Clinical ... it provides no extra funding and does not suggest what ... leaves medical staff with difficult decisions to make. , ...
Cached Biology News:Protect patients from exploitation by alternative medicines industry 2Chemotherapy temporarily affects the structures of the human brain 2Other patients bear the real cost of Herceptin 2
... Assay with FAM-Labeled Substrate (green fluorescence; ... measure serine protease activation • No ... FLISP Kits utilize cell-permeable, fluorescently labeled ... measure chymotrypsin-like activity in whole living ...
... Engine instrument is the cycler that ... thermal uniformity and swappable blocks ensure ... This rugged machine is more ... platform for new features and upgrades ...
... The Easy Cap tool provides ... seat domed double-locking caps in tubes ... has a wide end that firmly ... prevent accidental crushing when opening or ...
... Multiple Species Tissue Array (MSTA) slides were designed ... and tissues from multiple species. Tissue slices ... MSTA slide which can then be treated as ... or in situ hybridization. This ...
Biology Products: